Caris Life Sciences, Inc. Common Stock (CAI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Caris Life Sciences, Inc. Common Stock stock (CAI) is currently trading at $18.56. Caris Life Sciences, Inc. Common Stock PS ratio (Price-to-Sales) is 6.70. Analyst consensus price target for CAI is $32.80. WallStSmart rates CAI as Sell.
- CAI PE ratio analysis and historical PE chart
- CAI PS ratio (Price-to-Sales) history and trend
- CAI intrinsic value — DCF, Graham Number, EPV models
- CAI stock price prediction 2025 2026 2027 2028 2029 2030
- CAI fair value vs current price
- CAI insider transactions and insider buying
- Is CAI undervalued or overvalued?
- Caris Life Sciences, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- CAI Piotroski F-Score and Altman Z-Score
- CAI analyst price target and Smart Rating
Caris Life Sciences, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Caris Life Sciences, Inc. Common Stock (CAI) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth, institutional own.. Concerns around return on equity and price/book. Mixed signals suggest waiting for clearer direction before acting.
Caris Life Sciences, Inc. Common Stock (CAI) Key Strengths (4)
Keeps $30 of every $100 in revenue after operating costs
Revenue surging 125.40% year-over-year
52.11% held by institutions, strong professional interest
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Caris Life Sciences, Inc. Common Stock (CAI) Areas to Watch (4)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive at 9.0x book value
Premium valuation at 6.7x annual revenue
Supporting Valuation Data
Caris Life Sciences, Inc. Common Stock (CAI) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 4 register as strengths (avg 8.8/10) while 4 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth, Institutional Own.. Profitability is solid with Operating Margin at 30.20%. Growth metrics are encouraging with Revenue Growth at 125.40%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Price/Book. Some valuation metrics including Price/Sales (6.70), Price/Book (9.01) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -45.40%, Profit Margin at -8.39%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -45.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 125.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CAI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CAI's Price-to-Sales ratio of 6.70x trades at a deep discount to its historical average of 13.58x (31th percentile). The current valuation is 74% below its historical high of 26.27x set in Aug 2025, and 6% above its historical low of 6.32x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~18.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Caris Life Sciences, Inc. Common Stock (CAI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Caris Life Sciences, Inc. Common Stock is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 812M with 125% growth year-over-year. The company is currently unprofitable, posting a -8.4% profit margin.
Key Findings
Revenue growing at 125% YoY, reaching 812M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 29M in free cash flow and 37M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -8.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Caris Life Sciences, Inc. Common Stock maintain 125%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Caris Life Sciences, Inc. Common Stock.
Bottom Line
Caris Life Sciences, Inc. Common Stock is a high-conviction growth story with revenue accelerating at 125% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -8.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:32:38 AM
About Caris Life Sciences, Inc. Common Stock(CAI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The company is headquartered in San Francisco, California.